Advertisement

Picture Berlin Partner Voices Peter Seeberger Chemistry Transformation 650x100px
Collaboration › Details

OSE Immunotherapeutics–Selexis: cell line development, 201611– supply service access to research cell banks from SUREtechnology platform

 

Period Period 2016-11-15
  Successor OSE Immunotherapeutics–Selexis: cell line development, 201705– commercial license for access to RCBs from SUREtechnology platform
Organisations Partner, 1st OSE Immunotherapeutics S.A.
  Today OSE Pharma S.A.
  Group OSE Immunotherapeutics (Group)
  Partner, 2nd Selexis S.A.
  Group JSR Corporation (Group)
Products Product SUREtechnology Platform™ (Selexis)
  Product 2 Effi-7 (Effimune/OSE Immunotherapeutics/Servier)
Person Person Bocci, Marco (Selexis 201311– Director European Sales + Business Development before Quintiles)
     

   
Record changed: 2017-05-30

Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for OSE Immunotherapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group World of Partnering Opportunities 650x300px




» top